BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 31776631)

  • 21. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of [
    Stokke C; Nørgaard JN; Feiring Phillips H; Sherwani A; Nuruddin S; Connelly J; Schjesvold F; Revheim ME
    Mol Imaging Biol; 2022 Oct; 24(5):842-851. PubMed ID: 35501622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased Uptake of 68Ga-Pentixafor in Thymic Rebound After Chemotherapy in a Patient With Multiple Myeloma.
    Pan Q; Luo Y; Cao X; Li J
    Clin Nucl Med; 2021 Jan; 46(1):90-92. PubMed ID: 33181744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
    Ak I; Gulbas Z
    Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of [
    Liu M; Chen X; Ding H; Shu Q; Zheng Y; Chen Y; Cai L
    Mol Imaging Biol; 2024 Apr; ():. PubMed ID: 38627276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemokine Receptor 4-Targeted 68Ga-Pentixafor PET/CT in Response Assessment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT.
    Pan Q; Cao X; Luo Y; Li J; Li F
    Clin Nucl Med; 2021 Sep; 46(9):732-737. PubMed ID: 34172595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The potential utility of [
    Lan L; Liu H; Wang Y; Deng J; Peng D; Feng Y; Wang L; Chen Y; Qiu L
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):963-979. PubMed ID: 34410435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CXCR4-directed PET/CT with [
    Dreher N; Hahner S; Fuß CT; Schlötelburg W; Hartrampf PE; Serfling SE; Schirbel A; Samnick S; Higuchi T; Weich A; Lapa C; Rosenwald A; Buck AK; Kircher S; Werner RA
    Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1383-1394. PubMed ID: 38082196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic efficacy of C-X-C motif chemokine receptor 4-directed PET/CT in newly diagnosed head and neck squamous cell carcinoma - a head-to-head comparison with [
    Zhi Y; Werner RA; Schirbel A; Higuchi T; Buck AK; Kosmala A; Bley TA; Hagen R; Hackenberg S; Rosenwald A; Scherzad A; Gerhard-Hartmann E; Serfling SE
    Am J Nucl Med Mol Imaging; 2023; 13(5):208-216. PubMed ID: 38023816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor.
    Herrmann K; Lapa C; Wester HJ; Schottelius M; Schiepers C; Eberlein U; Bluemel C; Keller U; Knop S; Kropf S; Schirbel A; Buck AK; Lassmann M
    J Nucl Med; 2015 Mar; 56(3):410-6. PubMed ID: 25698782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [
    Haug AR; Leisser A; Wadsak W; Mitterhauser M; Pfaff S; Kropf S; Wester HJ; Hacker M; Hartenbach M; Kiesewetter-Wiederkehr B; Raderer M; Mayerhoefer ME
    Theranostics; 2019; 9(12):3653-3658. PubMed ID: 31281504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [
    Watts A; Singh B; Singh H; Bal A; Kaur H; Dhanota N; Arora SK; Mittal BR; Behera D
    Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1216-1227. PubMed ID: 36482077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary Results.
    Mayerhoefer ME; Jaeger U; Staber P; Raderer M; Wadsak W; Pfaff S; Kornauth C; Senn D; Weber M; Wester HJ; Skrabs C; Haug A
    Invest Radiol; 2018 Jul; 53(7):403-408. PubMed ID: 29642081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
    Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
    Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
    Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
    Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 68Ga-Pentixafor PET/CT Improves the Detection of Recurrent Myeloma in the Temporal Bone Masked by the Physiological 18F-FDG Uptake of the Brain and Extraocular Muscles.
    Pan Q; Luo Y; Cao X; Li J
    Clin Nucl Med; 2022 Apr; 47(4):e348-e350. PubMed ID: 35020649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using
    Buck AK; Haug A; Dreher N; Lambertini A; Higuchi T; Lapa C; Weich A; Pomper MG; Wester HJ; Zehndner A; Schirbel A; Samnick S; Hacker M; Pichler V; Hahner S; Fassnacht M; Einsele H; Serfling SE; Werner RA
    J Nucl Med; 2022 Nov; 63(11):1687-1692. PubMed ID: 35241482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical detection of chemokine receptor 4 expression in chronic osteomyelitis confirms specific uptake in 68Ga-Pentixafor-PET/CT.
    Bouter Y; Meller B; Sahlmann CO; Wolf BJ; Langer L; Bankstahl JP; Wester HJ; Kropf S; Meller J; Bouter C
    Nuklearmedizin; 2018 Sep; 57(5):198-203. PubMed ID: 30267402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas.
    Weich A; Werner RA; Buck AK; Hartrampf PE; Serfling SE; Scheurlen M; Wester HJ; Meining A; Kircher S; Higuchi T; Pomper MG; Rowe SP; Lapa C; Kircher M
    Diagnostics (Basel); 2021 Mar; 11(4):. PubMed ID: 33805264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
    Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
    Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.